▽BioToday-Home
●03/12 15:14
2025-03-12 Agomab社のALK5阻害薬が線維化狭窄ｸﾛｰﾝ病相手のPh2a試験の途中解析合格Agomab Therapeutics社のALK5阻害薬AGMB-129の線維化狭窄ｸﾛｰﾝ病（Fibrostenosing Crohn’s Disease､FSCD）相手のPh2a試験STENOVAの途中解析で安全性､薬物動態､標的部位着任のほどが及第しました｡ 4段落, 238文字2025-03-12 ｱﾄﾋﾟｰ性皮膚炎患者の約30%がAmgen/協和ｷﾘﾝのrocatinlimabでEASI-75達成Amgen/協和ｷﾘﾝの抗OX40抗体rocatinlimab（ﾛｶﾁﾝﾘﾏﾌﾞ）高用量単独投与で中等～重度ｱﾄﾋﾟｰ性皮膚炎（AD）患者のﾌﾟﾗｾﾎﾞ差し引き約30%（29.5%）が病状指標EASIの75%以上改善（EASI-75）を24週時点で達成しました｡ 5段落, 452文字2

▽ねいろうろうろ
●03/12 14:44
1 ｽｸｰﾙ･ｾﾐﾅｰ2 鉄道･飛行機3 ﾌｨｷﾞｭｱ4 経営･ﾋﾞｼﾞﾈｽ5 競馬･ｷﾞｬﾝﾌﾞﾙ6 将棋7 ﾎﾞﾗﾝﾃｨｱ8 科学9 ﾈｯﾄ･IT技術10 政治･経済

▽一石二鳥
●03/12 14:14
1 車･ﾊﾞｲｸ2 ｺﾚｸｼｮﾝ3 ｲﾍﾞﾝﾄ･祭り4 ﾈｯﾄ･IT技術5 将棋6 仮想通貨7 語学8 ﾎﾞﾗﾝﾃｨｱ9 ﾗｲﾌﾞ･ﾊﾞﾝﾄﾞ10 受験･勉強

▽The Journal of Experimental Medicine
●03/12 13:29
Article| March 06 2025PCK1 inhibits cGAS by competitive consumption of GTPWenxing Qin et al.This study unveils a novel mechanism by which the metabolic enzyme PCK1 hinders cGAS-STING activation by competitively consuming GTP, consequently fostering tumor immune evasion.

▽Nature: Science articles and news, scientific information and jobs: nature journal
●03/12 13:16
Alcohol and cancer risk: what you need to knowExperts weigh in on the risks of moderate drinking — and how people should assess them.How the NIH dominates the world’s health research — in chartsAbrupt cuts by the Trump administration to the US National Institutes of Health threaten progress in medical research globally.Nisha GaindNews10 Mar 2025NASA begins mass firings of scientists ahead of